$CADL News

Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey

B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12

CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4

HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Candel Therapeutics Q2 EPS $(0.52) Misses $(0.23) Estimate

CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity

Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up

Candel Therapeutics: Getting Closer, And Building Out More Paths

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston

Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential

CADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Candel Therapeutics Starts Pivotal Phase 3 AURORA Study Of Aglatimagene Besadenovec Plus Valacyclovir In Combination With Continued Pembrolizumab In Participants With Metastatic Non-Squamous Non-Small Cell Lung Cancer

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is Bullish